Item 1.01. Entry into a Material Definitive Agreement.

On August 10, 2020, Natus Medical Incorporated (the "Company") amended the terms of its five year credit agreement dated September 23, 2016 (the "Amended Credit Agreement") by and between the Company, JP Morgan Chase Bank, NA ("JP Morgan"), Citibank, NA ("Citibank"), and Wells Fargo Bank, NA ("Wells Fargo"). The Amended Credit Agreement extends the maturity date of the original agreement from September 23, 2021 to September 25, 2023, reduces the aggregate revolving credit facility from $225 million to $150 million, and amends certain covenants. As of August 11, 2020, a total of $87 million out of an available $150 million was outstanding under the Amended Credit Agreement.

The foregoing description of the Amended Credit Agreement does not purport to be complete and is qualified in its entirety by the terms of such Amended Credit Agreement. The Company intends to file the Amended Credit Agreement with the U.S. Securities and Exchange Commission as an exhibit to its next Quarterly Report on Form 10-Q.





                 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
Item 2.03.       Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 is hereby incorporated by reference into this Item 2.03.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses